OPRX News and Press, OptimizeRx Corporation From 04/05/22

ROCHESTER, Mich., April 05, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX),  a leading provider of point-of-care technology solutions helping patients start and stay on therapy, has been named to the Financial Times (“FT”)...

SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced that William Febbo, Chief Executive Officer and Director of OptimizeRx, has joined its board of directors, effective Marc...

OptimizeRx (NASDAQ:OPRX) is acquiring specialty drug prescription initiation platform EvinceMed and related assets. The company said EvinceMed delivers end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporti...

ROCHESTER, Mich., March 15, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX),  a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced a definitive agreement to acquire the Evin...

ROCHESTER, Mich., March 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy today announced that its senior vice president of corporate finan...

Image source: The Motley Fool. OptimizeRx Corporation (NASDAQ: OPRX) Q4 2021 Earnings Call Feb 24, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: OptimizeRx Corporation (OPRX) Q4 2021 Earnings Call Transcript

OptimizeRx Corporation. (OPRX) Q4 2021 Earnings Conference Call February 24, 2022, 04:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Andrew D’Silva - Senior Vice President of Corpo...

OptimizeRx press release (NASDAQ:OPRX): Q4 Non-GAAP EPS of $0.22 beats by $0.18. Revenue of $20.3M (+23.6% Y/Y) beats by $5.5M. For further details see: OptimizeRx Non-GAAP EPS of $0.22 beats by $0.18, revenue of $20.3M beats by $5.5M

Fourth quarter revenue Up 24% to $20.3 million, gross profit margin of 61% Introduction of key performance indicators (KPIs) representing “land and expand” strategy with key customer accounts Cash flow positive from operations of $0.7 million in 2021 ROCHES...

ROCHESTER, Mich., Feb. 22, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the launch of a large-scale therapy initiation pr...